Estimates of risk, empirical treatment observations, and unexpected laboratory findings reveal the complexity of nephrogenic systemic fibrosis.
Whitney A
WA
High
D003131:Combined Modality Therapy; D003287:Contrast Media / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D005682:Gadolinium / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D008297:Male; D054989:Nephrogenic Fibrosing Dermopathy / Q000139:chemically induced / Q000473:pathology* / Q000628:therapy*; D019370:Observation; D017893:Photopheresis; D010956:Plasmapheresis / Q000379:methods; D006435:Renal Dialysis / Q000379:methods; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000379:methods
D003287:Contrast Media; D007166:Immunosuppressive Agents; D005682:Gadolinium